• 1 Department of Urology, St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea
  • 2 Department of Strategic Investigation on Comprehensive Cancer Network, Graduate School of Interdisciplinary Information Studies, University of Tokyo, Tokyo, Japan
  • 3 Beijing United Family Hospital and Clinics, Beijing, China
  • 4 SH Ho Urology Centre, The Chinese University of Hong Kong, Hong Kong, China
  • 5 Department of Urology, Airlangga University/Dr Soetomo General Hospital of Surabaya, Surabaya, East Java, Indonesia
  • 6 Department of Urology, Dr Cipto Mangunkusumo Hospital/Faculty of Medicine, University of Indonesia, Depok City, West Java, Indonesia
  • 7 Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea
  • 8 Department of Urology Gangnam Severance Hospital, Yonsei University College of Medicine
  • 9 Department of Urology, Chugbuk National Medical University Hospital
  • 10 Department of Surgery, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
Jpn J Clin Oncol, 2019 Jun 01;49(6):581-586.
PMID: 31141613 DOI: 10.1093/jjco/hyz053


The Asian Prostate Cancer (A-CaP) Study is an Asia-wide prospective registry study for surveying the treatment outcome of prostate cancer patients who have received a histopathological diagnosis. The study aims to clarify the clinical situation for prostate cancer in Asia and use the outcomes for the purposes of international comparison. Following the first meeting in Tokyo on December 2015, the second meeting in Seoul, Korea 2016, the third meeting in Chiang Mai, Thailand, on October 2017, the fourth meeting was held in Seoul, again on August 2018 with the participation of members and collaborators from 13 countries and regions. In the meeting, participating countries and regions presented the current status of data collection and the A-CaP office presented a preliminary analysis of the registered cases received from each country and region. Participants discussed ongoing challenges relating to data cleaning and data up-dating which is the next step of the A-CaP study following the data collection phase between 2016 and 2018. There was specific difference in term of the patient characteristics, and initial treatment pattern among East Asia, Southeast Asia and Turkey, and Jordan. Finally, a close relationship between prevalence of PSA test and disease stage of the patients at diagnosis in Japan and Malaysia was discussed.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.